Safety and Immune Response of Increasing Doses of OVX836 After Intramuscular or Intranasal Administrations in Healthy Subjects
NCT ID: NCT03594890
Last Updated: 2022-09-22
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
72 participants
INTERVENTIONAL
2018-06-12
2019-08-07
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This clinical trial will evaluate the safety and the immune response of increasing doses of OVX836 after intramuscular or intranasal administrations in healthy volunteers.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Efficacy, Immunogenicity and Safety of OVX836 Influenza Vaccine 480μg
NCT05569239
Immunogenicity and Safety of Three Dose Levels of OVX836 Candidate Vaccine Against Influenza in Healthy Volunteers.
NCT05060887
Safety and Immune Response of One Dose of OVX836 at Two Dose Levels, in Comparison to Influvac TetraTM, After Intramuscular Administration in Healthy Subjects Aged 18-65 Years
NCT04192500
Safety and Immunogenicity of Two Dose Levels of OVX836 Influenza Vaccine as a Booster on Participants Previously Administered With OVX836
NCT06582277
Immunogenicity and Safety of the Concomitant Administration of OVX836 Influenza Vaccine, Quadrivalent Inactivated Influenza Vaccines and Placebo in Healthy Subjects.
NCT05734040
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The OVX836 recombinant vaccine is based on the well conserved nucleoprotein of the Influenza virus.
Three different dose levels of OVX836 (30µg, 90µg, 180µg) will be assessed sequentially and administered either by the intramuscular route (Study Part A) or by the intranasal route (Study Part B).
There will be 6 cohorts in total with one cohort testing one dose level and one route of administration. Each study cohort will be composed of 12 subjects, with 9 subjects receiving the OVX836 vaccine and 3 subjects receiving the placebo. Each subject will receive one administration of OVX836 or placebo on Day 1 and one administration on Day 29.
The study duration for each subject is approximately 5 months.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
SEQUENTIAL
PREVENTION
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
OVX836 (Intramuscular)
OVX836 is a recombinant Influenza vaccine based on the NP of the Influenza virus. OVX836 vaccine is a ready to use sterile liquid clear and colourless solution, presented in 2 mL glass vials filled with 1.2 mL solution. It contains 300 µg/mL of OVX836 vaccine and is formulated without adjuvant.
3 Dose levels tested: 30µg, 90 µg and 180 µg.
OVX836 (Intramuscular)
2 consecutive administrations of OVX836 vaccine at Day 1 and Day 29.
Placebo (Intramuscular)
The Placebo, is Sodium Chloride 0.9 % ready to use sterile solution. The volume of placebo to be administered will be similar to the one of the experimental vaccine.
Placebo (Intramuscular)
2 consecutive administrations of placebo at Day 1 and Day 29.
OVX836 (Intranasal)
OVX836 is a recombinant Influenza vaccine based on the NP of the Influenza virus. OVX836 vaccine is a ready to use sterile liquid clear and colourless solution, presented in 2 mL glass vials filled with 1.2 mL solution. It contains 300 µg/mL of OVX836 vaccine and is formulated without adjuvant.
3 Dose levels tested: 30µg, 90 µg and 180 µg.
OVX836 (Intranasal)
2 consecutive administrations of OVX836 vaccine at Day 1 and Day 29.
Placebo (Intranasal)
The Placebo, is Sodium Chloride 0.9 % ready to use sterile solution. The volume of placebo to be administered will be similar to the one of the experimental vaccine.
Placebo (Intranasal)
2 consecutive administrations of placebo at Day 1 and Day 29.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
OVX836 (Intramuscular)
2 consecutive administrations of OVX836 vaccine at Day 1 and Day 29.
Placebo (Intramuscular)
2 consecutive administrations of placebo at Day 1 and Day 29.
OVX836 (Intranasal)
2 consecutive administrations of OVX836 vaccine at Day 1 and Day 29.
Placebo (Intranasal)
2 consecutive administrations of placebo at Day 1 and Day 29.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Overtly healthy male or female subjects, as determined by medical history and medical examination.
3. Between the ages of 18 and 49 years, inclusive, on screening.
4. Between the Body Mass Index of 18 and 24 kg/m2, inclusive, on screening.
5. Clinical laboratory test results within normal reference range, or results with acceptable deviations that are judged to be Non Clinically Significant by the Investigator.
6. Blood Pressure and Heart Rate within normal reference range, or results with acceptable deviations that are judged to be Non Clinically Significant by the Investigator.
7. Are reliable and willing to make themselves available for the duration of the study and are willing to follow study procedures.
Exclusion Criteria
2. History of significant medical illness such as auto immune diseases, immune deficiency, uncontrolled diabetes or hypertension, heart or renal or hepatic diseases, as judged by the investigator.
3. For female subjects: pregnant or breast-feeding or of childbearing potential without appropriate contraceptive methods or with positive pregnancy test at screening.
4. Having received another vaccination within 3 months prior to screening.
5. Plan to receive other vaccine during the study period.
6. Administration of any investigational or non-registered drug or vaccine within 3 months prior to the first administration of study vaccine.
7. History of receiving blood or blood component or IgG within 3 months prior to screening.
10. Individuals with any progressive or severe neurological disorder, seizure disorder or Guillain-Barré syndrome.
11. Individuals with behavioral or cognitive impairment or psychiatric disease that, in the opinion of the Investigator, may interfere with the subject's ability to participate in the study.
12. History of alcoholism and/or drug abuse or tabagism (above 10 cigarettes a day).
13. Treatment that can affect immune response such as systemic or high dose inhaled corticosteroids (\>800µg/day beclometasone or equivalent), radiation treatment, cytotoxic drugs or chronic non-steroidal anti-inflammatory drugs (more than 4 weeks), interferon, immunomodulators, allergy shots, as judged by the Investigator.
14. Positive test for HIV, HBV or HCV at screening.
15. History of severe allergic reactions and/or anaphylaxis or serious adverse reactions to vaccines and antibiotics.
16. Any contraindication to intranasal or intramuscular administration, as judged by the Investigator.
17. Individuals with history of any illness that, in the opinion of the Investigator, might interfere with the results of the study or pose additional risk to the subjects due to participation in the study.
18. Sponsor employees or Investigator site personnel directly affiliated with this study, and their immediate families. Immediate family is defined as a spouse, parent, child or sibling, whether biological or legally adopted.
18 Years
49 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Aepodia
INDUSTRY
Osivax
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pierre Van Damme, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Centre for the Evaluation of Vaccination, University of Antwerp
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Centre for the Evaluation of Vaccination, University of Antwerp
Antwerp, , Belgium
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
Sponsor
Phase 1 Randomized, Placebo-Controlled, Dose-Escalating Study to Evaluate OVX836, a Nucleoprotein-Based Influenza Vaccine: Intramuscular Results
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
OVX836-001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.